Full Breakdown
Eli Lilly to Acquire Ajax Therapeutics in Up-to-$2.3 B Deal Targeting Blood Cancers
4/28/2026, 11:31:44 AM
Transaction Overview
On 27 April 2026 Eli Lilly and Company (NYSE: LLY) announced a definitive agreement to acquire Ajax Therapeutics, Inc. for a total cash consideration of up to $2.3 billion. The structure combines an undisclosed upfront payment with milestone-based payments linked to clinical and regulatory achievements. Closing is subject to customary conditions, including antitrust clearance under the Hart-Scott-Rodino Act, and the transaction will be reflected in Lilly’s GAAP results after completion.
Strategic Background
Lilly’s recent acquisitions of Scorpion Therapeutics, Orna Therapeutics and Kelonia Therapeutics illustrate an aggressive expansion into oncology. Ajax, founded in 2019 with Lilly as a founding strategic investor and a partnership with Schrödinger, Inc., focuses on next-generation Janus kinase 2 (JAK2) inhibitors for myeloproliferative neoplasms (MPNs). The deal adds a blood-cancer platform to a portfolio previously dominated by solid-tumor programs and GLP-1 obesity/diabetes products.
Lead Asset AJ1-11095
AJ1-11095 is a first-in-class, once-daily oral Type II JAK2 inhibitor currently in a Phase 1 trial (AJX-101) for patients with myelofibrosis who have previously received a Type I JAK2 inhibitor. Unlike approved Type I inhibitors that bind the active conformation of JAK2, AJ1-11095 binds the Type II conformation, a design intended to achieve deeper and more durable disease control. The trial began in late 2024; dose selection is expected in 2026, with proof-of-concept data slated for later that year. The compound holds FDA orphan-drug status for myelofibrosis and is also being developed for polycythemia vera.
Key Figures
- Jacob Van Naarden – Executive Vice President, President of Lilly Oncology, and Head of Corporate Business Development.
- Martin Vogelbaum – Co-founder and Chief Executive Officer of Ajax Therapeutics.
- Ross Levine, MD – Chief Scientific Officer at Memorial Sloan Kettering Cancer Center and chair of Ajax’s scientific advisory board.
Data & Statistics
- Deal value: up to $2.3 billion cash.
- AJ1-11095: Phase 1, oral, Type II JAK2 inhibitor.
- Clinical timeline: Phase 1 start 2024; proof-of-concept data 2026; dose selection 2026.
- Orphan-drug designation for myelofibrosis.
Why It Matters
Current JAK2 inhibitors provide symptomatic relief but often lose efficacy, leading to treatment discontinuation. AJ1-11095’s distinct binding mode could address resistance, offering a potential new therapy for patients with myelofibrosis and polycythemia vera—conditions with significant unmet medical need. The acquisition expands Lilly’s hematologic oncology capabilities and diversifies its revenue base beyond obesity and diabetes drugs.
Official Statements & Responses
Lilly emphasized that its blood-cancer expertise will accelerate AJ1-11095 toward registrational trials, aiming to deliver a durable therapy for patients and hematologists. Ajax’s leadership expressed gratitude to investigators and patients participating in the Phase 1 study and affirmed confidence that Lilly will advance the program through later-stage development.
Verbatim Quotes
- “As a founding strategic investor in Ajax, Lilly has long believed in the approach and is excited about the potential for AJ1-11095 to deliver deeper and more durable efficacy than available treatments with a tolerability profile that would allow for patients to remain on therapy longer and be used across both the first- and second-line settings,” — Jacob Van Naarden, EVP & President, Lilly Oncology
- “We look forward to the presentation of clinical proof-of-concept data later in 2026, rapidly advancing AJ1-11095 into registrational clinical trials, and using our expertise in blood cancer to hopefully deliver another important new medicine to patients and hematologists.” — Jacob Van Naarden, EVP & President, Lilly Oncology
- “We started Ajax to build on the work of its five scientific founders, including Ross Levine, MD, chief scientific officer at Memorial Sloan Kettering Cancer Center and chair of Ajax's scientific advisory board, who sought to develop a novel class of selective and more potent JAK2 inhibitors to address the significant unmet need of patients with MPNs,” — Martin Vogelbaum, Co-Founder & CEO, Ajax Therapeutics
- “could offer a competitive therapy in MPNs where traditional JAK inhibitors have failed,” — Evan Seigerman, BMO analyst
What’s Next
Lilly expects proof-of-concept data from the AJX-101 trial later in 2026, followed by dose-selection decisions and entry into registrational studies. The transaction will close pending regulatory approvals, after which Lilly’s oncology unit will integrate AJ1-11095 into its development pipeline.
